NewAmsterdam Revenue Per Share from 2010 to 2025

NAMSW Stock   14.11  0.28  1.95%   
NewAmsterdam Pharma Revenue Per Share yearly trend continues to be fairly stable with very little volatility. Revenue Per Share will likely drop to 0.17 in 2025. Revenue Per Share is the amount of revenue generated by NewAmsterdam Pharma per share of stock, calculated by dividing total revenue by the average number of shares outstanding. View All Fundamentals
 
Revenue Per Share  
First Reported
2010-12-31
Previous Quarter
0.18
Current Value
0.17
Quarterly Volatility
1.97050965
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check NewAmsterdam Pharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among NewAmsterdam Pharma's main balance sheet or income statement drivers, such as Tax Provision of 32.6 K, Net Interest Income of 4.1 M or Interest Income of 13.6 M, as well as many indicators such as Price To Sales Ratio of 67.95, Dividend Yield of 0.0 or PTB Ratio of 3.01. NewAmsterdam financial statements analysis is a perfect complement when working with NewAmsterdam Pharma Valuation or Volatility modules.
  
Check out the analysis of NewAmsterdam Pharma Correlation against competitors.
For more information on how to buy NewAmsterdam Stock please use our How to Invest in NewAmsterdam Pharma guide.

Latest NewAmsterdam Pharma's Revenue Per Share Growth Pattern

Below is the plot of the Revenue Per Share of NewAmsterdam Pharma over the last few years. It is the amount of revenue generated by a company per share of stock, calculated by dividing total revenue by the average number of shares outstanding. NewAmsterdam Pharma's Revenue Per Share historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in NewAmsterdam Pharma's overall financial position and show how it may be relating to other accounts over time.
ViewLast Reported 0.37310 Years Trend
Slightly volatile
   Revenue Per Share   
       Timeline  

NewAmsterdam Revenue Per Share Regression Statistics

Arithmetic Mean4.14
Geometric Mean2.67
Coefficient Of Variation47.60
Mean Deviation1.49
Median5.06
Standard Deviation1.97
Sample Variance3.88
Range4.9013
R-Value(0.68)
Mean Square Error2.25
R-Squared0.46
Significance0
Slope(0.28)
Total Sum of Squares58.24

NewAmsterdam Revenue Per Share History

2025 0.17
2024 0.18
2023 0.16

About NewAmsterdam Pharma Financial Statements

NewAmsterdam Pharma investors use historical fundamental indicators, such as NewAmsterdam Pharma's Revenue Per Share, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in NewAmsterdam Pharma. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Revenue Per Share 0.18  0.17 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for NewAmsterdam Stock Analysis

When running NewAmsterdam Pharma's price analysis, check to measure NewAmsterdam Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NewAmsterdam Pharma is operating at the current time. Most of NewAmsterdam Pharma's value examination focuses on studying past and present price action to predict the probability of NewAmsterdam Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NewAmsterdam Pharma's price. Additionally, you may evaluate how the addition of NewAmsterdam Pharma to your portfolios can decrease your overall portfolio volatility.